2 billion injections will be the first to be rated! Luoxin PharmaceuticalS antimicrobial application accepted

Pharmaceutical Network July 6th, July 3, Luoxin Pharmaceuticals issued a notice that its subsidiary Shandong Luoxin Pharmaceuticals received the State Drug Administration issued the Klinmycin phosphate injection listing application "acceptance notice." According to Minne.com, sales of klinmycin injections at the end of public medical institutions in China reached 2.302 billion yuan in 2019The data show that klinmycin phosphate is a derivative of 2 hydroxyl phospholipidization of klinmycin, which is hydrolysised in the body after injection, forming klinmycin and exerting antibacterial activityKlinmycin plays an antibacterial role by inhibiting the synthesis of bacterial proteins, which has antibacterial effects on most gram-positive bacteria and some anaerobic gram-negative bacteriaIn recent years, China's public medical institutions terminal klinmycin injection sales (units: 10,000 yuan)-meter net data show that in 2019 China's urban publichospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal klinmycin injection sales reached 2.302 billion yuanDeveloped by Pharmacia And Upjohn Co, the Klinmycin phosphate injection was approved by the U.SFDA in 1972 for listing a product called Cleocin PhosphateAt present, Klinmycin phosphate injection research products are not listed in China, a total of 74enterprisesKlinmycin phosphate injection approved to marketUp to now, Klinmycin phosphate injection has not been evaluated by enterprises, Jiangsu Shenlong Pharmaceuticals, Shandong Weizhi Encyclopedia Pharmaceuticals, Hunan Wuzhou Tong Pharmaceutical Co., China's consistency evaluation supplementary application in the review and approval (in the drug review center), Guangdong Xingyi Pharmaceuticals, Guangzhou Magenta Pharmaceuticals, Guang'an Kate Pharmaceuticals to copy 3 categories of listing applications submitted in the review and approval (in the drug review center)Luoxin Pharmaceuticals said that the Shandong Luoxin Pharmaceuticals Klinmycin phosphate injection to copy 3 categories of submitted listing applications, approved can be directly listed for sale, as if through consistency evaluation, will further enrich the company's product line, enhance market competitivenessMinnet White Feather FinishingSource: Minnet Net Database, Announcement of Listed Companies